GTH Genetron Holdings ADS (N shares)

Genetron Health to Announce Second Quarter Unaudited Financial Results and Host Investor Call on August 6, 2020

Genetron Health to Announce Second Quarter Unaudited Financial Results and Host Investor Call on August 6, 2020

BEIJING, July 27, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology company in China that specializes in offering molecular profiling tests, today announced that it will report unaudited financial results for the second quarter ended June 30, 2020, on August 6, 2020, before the US market open.

Management will host a conference call for investors at 8:30 a.m. ET (8:30 p.m. Beijing time) on Thursday, August 6, 2020. The conference call can be accessed by dialing the following numbers:

United States:
China Domestic:400-620-8038
Hong Kong:
International:
Conference ID: 1969177

Participants are encouraged to dial into the call at least 15 minutes in advance due to high call volumes.

A replay will be accessible through September 6, 2020, by dialing the following numbers: 

United States:
International: 
Conference ID: 1969177

A simultaneous webcast of the conference call will be available on the "News and Events" page of the Investors section of the Company's website. A replay of the webcast will be available for 30 days following the event. For more information, please visit ir.genetronhealth.com.

About Genetron Holdings Limited

Genetron Holdings Limited (“Genetron Health” or the “Company”) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit ir.genetronhealth.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may”, “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

Investor Relations Contacts

US:

Hoki Luk

Head of Investor Relations

Email:

Phone: +1 (408) 204-5343

Stephanie Carrington

Westwicke, an ICR Company

Email:

Phone: +1 (646) 277-1282

Asia:

Bill Zima

ICR, Inc.

Email:

Media Relations Contact

Edmond Lococo

ICR



Mobile: 08

EN
27/07/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Genetron Holdings ADS (N shares)

 PRESS RELEASE

Genetron Health Announces Completion of Going Private Transaction

Genetron Health Announces Completion of Going Private Transaction BEIJING, March 28, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today the completion of its merger (the “Merger”) with Genetron New Co Limited (“Merger Sub”), pursuant to the previously announced agreement and plan of merger, dated as of October 11, 2023 (the “Merger Agreement”),...

 PRESS RELEASE

Genetron Health Announces Shareholders’ Approval of Merger Agreement

Genetron Health Announces Shareholders’ Approval of Merger Agreement BEIJING, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that at an extraordinary general meeting of shareholders (the “EGM”) held today, the Company’s shareholders voted in favor of, among other things, the proposal to authorize and approve the previously announce...

 PRESS RELEASE

Genetron Health to Hold Extraordinary General Meeting of Shareholders

Genetron Health to Hold Extraordinary General Meeting of Shareholders BEIJING, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that it has called an extraordinary general meeting of shareholders (the “EGM”), to be held at on February 21, 2024 at 9:00 a.m. (Beijing time) at 1/F, Building 11, Zone 1, No. 8 Life Science Parkway, Changp...

 PRESS RELEASE

Genetron Health Enters into Definitive Merger Agreement for Going Priv...

Genetron Health Enters into Definitive Merger Agreement for Going Private Transaction BEIJING, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that it has entered into a definitive Agreement and Plan of Merger (the “Merger Agreement”) with New Genetron Holding Limited (“Parent”) and Genetron New Co Limited (“Merger Sub”), a wholly-o...

 PRESS RELEASE

Genetron Health Regains Compliance With Nasdaq Minimum Bid Price Requi...

Genetron Health Regains Compliance With Nasdaq Minimum Bid Price Requirement BEIJING, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that the Company had received a notification letter (“Compliance Notice”) from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”), dated January 17, 2023, ind...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch